Novartis Discontinues Mid-Stage Lupus Trial In Latest Pipeline Setback

The multi-location study aimed to evaluate the efficacy, safety, and tolerability of iptacopan (LNP023) in addition to standard-of-care treatment in lupus.
Read the full report on Asianet Newsable
Story file
- Section
- Science
- First reported by
- Asianet Newsable
- Reporter
- stocktwits inc
- Published
- Saturday, 17 October 2026, 4:05 am IST
- Coverage
- One outlet so far
How this page works. The Headline Update lists this report from Asianet Newsable with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.